EATG » MSF at AIDS 2018: press releases, updates, publications

MSF at AIDS 2018: press releases, updates, publications

Press releases/Updates

 

  • Pfizer and GSK’s HIV/AIDS division, ViiV, prevents children with HIV from getting needed medicine

As the annual global HIV/AIDS conference gets underway in Amsterdam, Médecins Sans Frontières (MSF) is calling out ViiV Healthcare – a division of US and UK pharmaceutical corporations Pfizer and GlaxoSmithKline, plus Japan’s Shionogi – for preventing children with HIV from getting child-appropriate formulations of a critical HIV medicine, dolutegravir.

Read the press release here.

 

 

****************

A list of MSF’s publications released for AIDS 2018

Briefing documents

 

  • Towards peer-led HIV and SRH services for sex workers and men having sex with men
    Experience from Médecins Sans Frontières in Malawi and Mozambique

Globally, HIV prevalence among female sex workers (SW) and men who have sex with men (MSM) is 12 and 19 times higher, respectively, than in the general population. Eighty per cent of new HIV infections outside of sub-Saharan Africa occur among these key populations and their sexual partners. In high prevalence countries in sub-Saharan Africa, 25 per cent of new infections occur amongst this group.

This briefing document aims to share the experience of MSF programmes in adapting HIV treatment and sexual and reproductive health (SRH) services to the needs of SW and MSM groups in Malawi and Mozambique.

Access the briefing document here.

 

  • Stopping Senseless Deaths: Overcoming access barriers to affordable, lifesaving diagnostics and treatments for HIV and opportunistic infections

Around 25 per cent of people living with HIV do not know their status and only 59 per cent are receiving treatment. Millions of people still remain at risk for opportunistic infections (OIs) and death.

This technical brief analyses access barriers to affordable, lifesaving diagnostics and treatments for HIV and OIs, including adult and paediatric formulations of dolutegravir – a highly effective and tolerable HIV integrase inhibitor that replaces efavirenz in first-line treatment regimens. Updated antiretroviral drug pricing information is also provided.

Access the briefing document here.